



Enanta Pharmaceuticals Appoints Pharmaceutical Veteran David Poorvin, Ph.D. to Board of Directors and Announces Key Hire to Clinical Development Team

WATERTOWN, Mass. February 22, 2005 – Enanta Pharmaceuticals, Inc. today announced that David Poorvin, Ph.D. has been named to the Company's Board of Directors. Dr. Poorvin brings more than 30 years of experience in the pharmaceutical industry to Enanta's Board.

"David Poorvin brings vast pharmaceutical industry experience and an outstanding track record in both business development and clinical research. We look forward to David's contributions to the Board and his strategic insight and perspective as the Company continues to expand its product pipeline and advance its product candidates toward the market," stated Jay R. Luly, Ph.D., President, Chief Executive Officer and Director of Enanta Pharmaceuticals.

Dr. Poorvin spent over twenty years at Schering Plough Corporation, serving in a variety of leadership roles, including Vice President of Business Development and Director of Clinical Research. Prior to Schering Plough, he served as Director of Clinical Research at Pfizer. During his 14-year business development tenure at Schering Plough he was involved in negotiating significant licenses and joint ventures as well as the acquisition of numerous pharmaceutical products and technologies. He received a B.A. degree from Hunter College of the City University of New York and his Ph.D. from Rutgers University, where he was awarded a post-doctoral fellowship in cardiovascular research.

Additionally, Enanta announced today that Dr. Maria Paris, M.D. will join Enanta as Senior Medical Director. Prior to joining Enanta, Dr. Paris held various clinical development positions at Abbott Laboratories from 1998 to 2004, most recently as Medical Director. Dr. Paris has over 20 years of clinical development experience in infectious diseases and has managed Phase 1 through Phase 4 studies for numerous anti-bacterials and anti-virals, including cethromycin, Omnicef™, and Kaletra™. She received her Medical Degree from Autonomous College of Medical Sciences of Central America of Costa Rica and conducted a fellowship in Pediatric Infectious Diseases at the University of Texas, Southwestern Medical Center at Dallas.

"The extensive infectious disease and medical expertise Maria brings to our drug development team will play an important role as we continue to expand our product pipeline," said Yat Sun Or, Ph.D. Senior Vice President of Research and Development of Enanta Pharmaceuticals. "As we continue to advance our lead clinical candidate EP-013420 through the clinic, Maria's clinical and regulatory experiences will be invaluable."

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. The heart of Enanta is its commitment to innovative chemistry that surpasses traditional medicinal chemistry approaches. The Company's successful integration of chemistry

FOR IMMEDIATE RELEASE

with biology has created a new class of macrolide and ketolide antibiotics that overcome bacterial resistance. Additionally, Enanta has discovered antiviral agents targeted against the Hepatitis C virus (HCV). Enanta is a privately held company with offices in Watertown, MA. More information about the company can be found at www.enanta.com.

For *Investor Relations*, please contact:

Paul Mellett

Vice President and Chief Financial Officer

(617) 607-0761

pmellett@enanta.com

For *Public Relations*, please contact MacDougall Biocommunications:

Kari Lampka

(508) 647-0209

kari@macbiocom.com

###